Author

J. M. Hughes

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Evolutionary Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:clustering· 1 Research Focus:differential expression· 1

Frequent Co-Authors

N. E. Sealover· 2 shared R. L. Kortum· 2 shared A. J. Linke· 1 shared B. Daley· 1 shared B. R. Daley· 1 shared C. Rao· 1 shared D. Chatterjee· 1 shared D. H. Huisman· 1 shared

Activity by Year

2022-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

N. E. Sealover

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Evolutionary BiologybioRxivMar 24, 2023

Unravelling the mystery of endemic versus translocated populations of the endangered Australian lungfish (Neoceratodus forsteri)

R. Biello, S. Ghirotto, D. J. Schmidt…·G. Bertorelle

This study uses genetic markers and Approximate Bayesian Computation to determine if Australian lungfish populations are endemic or translocated, finding evidence of an endemic gene pool in specific rivers.

DOI 10.1111/mec.17266

DNA methylationstatistical model

𝕏 PostBluesky

Cancer BiologybioRxivJan 27, 2023

In situ modeling of acquired resistance to RTK/RAS pathway targeted therapies

N. E. Sealover, P. L. Theard, J. M. Hughes…·R. L. Kortum

This paper introduces an in situ resistance assay to model acquired resistance to RTK/RAS pathway targeted therapies and shows SHP2 inhibitors can delay resistance development.

DOI 10.1016/j.isci.2023.108711

humanbulk RNA-seq

𝕏 PostBluesky

Cancer BiologybioRxivDec 6, 2022

SOS1 and KSR1 modulate MEK inhibitor responsiveness to target resistant cell populations based on PI3K and KRAS mutation status

B. Daley, H. M. Vieira, C. Rao…·R. L. Kortum

This study shows that targeting SOS1 or KSR1 enhances MEK inhibitor efficacy and prevents resistance in KRAS-mutated cancers, depending on specific KRAS and co-mutation status.

DOI 10.1073/pnas.2313137120

humanbulk RNA-seq

𝕏 PostBluesky